- Home
- ZIP vs ANL Comparison
ZIP vs ANL Comparison
Compare ZIP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZIP | ANL |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 350.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ZIP | ANL |
|---|---|---|
| Price | $2.51 | $10.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.88 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.1M | 759.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $474,001,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $0.88 |
| 52 Week High | $7.24 | $12.09 |
Technical Indicators
Market Signals| Indicator | ZIP | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 73.27 |
| Support Level | N/A | $1.36 |
| Resistance Level | $4.85 | $12.09 |
| Average True Range (ATR) | 0.18 | 0.76 |
| MACD | 0.10 | -0.20 |
| Stochastic Oscillator | 83.10 | 27.68 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.